Contrasting Seaport Therapeutics (SPTX) and The Competition

Seaport Therapeutics (NASDAQ:SPTX) is one of 907 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Seaport Therapeutics to related companies based on the strength of its institutional ownership, valuation, dividends, profitability, risk, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Seaport Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2	3	5	0	2.30
Seaport Therapeutics Competitors	7667	13617	25478	989	2.41

Seaport Therapeutics presently has a consensus price target of $38.40, suggesting a potential upside of 57.38%. As a group, “Pharmaceuticals” companies have a potential upside of 31.93%. Given Seaport Therapeutics’ higher possible upside, research analysts clearly believe Seaport Therapeutics is more favorable than its competitors.

Profitability

This table compares Seaport Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Seaport Therapeutics Competitors	-2,313.75%	-223.79%	-17.58%

Earnings and Valuation

This table compares Seaport Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Seaport Therapeutics	N/A	-$74.88 million	-2.01
Seaport Therapeutics Competitors	$16.71 billion	$3.10 billion	540.25

Seaport Therapeutics’ competitors have higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Seaport Therapeutics competitors beat Seaport Therapeutics on 8 of the 12 factors compared.

About Seaport Therapeutics

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.